Cellceutix Corp (CTIX) 4.2900 $CTIX
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
Marketwired - Mon Dec 22, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide additional information from the Company's recently completed Phase 2b clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), as well as information on other pipeline developments.
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.13 (+0.05), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), BCLI: 3.85 (+0.22), OMER: 22.09 (+0.48), NVS: 93.91 (+0.66)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.03), PFNX: 7.33 (-0.05), INO: 9.11 (-0.09), CMRX: 36.80 (+0.70), RPTP: 9.34 (+0.56), IBIO: 0.68 (-0.04), ANAC: 30.58 (+0.16), PFE: 31.42 (-0.03), GNCA: 7.42 (-0.11), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)
Otitis Media - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/2cm2ck/otitis_media) has announced the addition of the "Otitis Media - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Otitis Media - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alcon, Inc. - GlaxoSmithKline plc - Yuhan Corporation - Arbor Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Otonomy, Inc. - Cellceutix Corporation - Serum Institute of India Limited - BCO Pharma Ltd For more information visit http://www.researchandmarkets.com/research/2c...itis_media
GSK: 42.85 (+0.11), OTIC: 32.26 (+0.65)
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin
Marketwired - Wed Dec 10, 6:40AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis. Cellceutix conducted a Phase 1 study which demonstrated that the bioavailability of the active component of Prurisol (abacavir) was the same or lower than that of the marketed drug Ziagen(R) (abacavir sulfate). FDA noted at the end-of-Phase 1 meeting on December 8, 2014 that, pending the full review of the Phase 1 data, long-term safety data for Prurisol in the treatment of psoriasis would not be required.
Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 57.46 (+0.25), PBS.VN: 0.015 (unch), NVS: 93.91 (+0.66)
Cellceutix jumps on QIDP tag
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 12:23PM CST
CBST: 100.29 (-0.09)
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
Marketwired - Mon Dec 08, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix's planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company's lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.
Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.38 (unch)
Super Stock Profits OTC Daily Trading News: Cellceutix Corp, Virtus Oil and Gas Corp, Solar 3D, Inc. Alkame Holdings, Inc.
PR Newswire Europe - Wed Nov 26, 7:39AM CST
LONDON, September 30, 2014 /PRNewswire/ --
Cellceutix: December to Be Momentous Month in Company's History
Marketwired - Mon Nov 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the completion of the ninth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The safety committee overseeing the clinical trial will be meeting in the first week of December to review safety data and discuss a possible dose escalation for the tenth cohort.
These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
ACCESSWIRE - Wed Nov 12, 8:53AM CST
CORAL GABLES, FL / ACCESSWIRE / November 12, 2014 / The midterm elections are still fresh in our minds and as several sectors have suffered due to the Republican party taking control, others have prospered. Moreover medical stocks have benefited greatly from this recent turn-over of power on Capitol Hill as certain changes are being made to the Affordable Care Act. Over the last week, companies involved in the healthcare and biotech sectors have enjoyed more of a marketwide revival in stock price appreciation.
Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014
Marketwired - Tue Nov 11, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antibiotic applications, is pleased to report that enrollment of the first patient in the Company's Phase 2 clinical trial of Brilacidin-OM for oral mucositis, an often debilitating effect of certain cancer therapies, is targeted for December 2014. Procedural work is being conducted at University of Texas MD Anderson Cancer Center as well as other clinical sites participating in the study. Cellceutix will soon be updating www.clinicaltrials.gov to reflect the start of the trial.
Retinoblastoma Therapeutics Pipeline Review, H2 2014 - 6 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5rnnw/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Neotropix, Inc. - Cellceutix Corporation - Recombio S.L - Icon Bioscience, Inc. - RXi Pharmaceuticals Corporation Drug Profiles - NTX-010 - racotumomab - Kevetrin - BL-8040 - melphalan - RNAi Oligonucleotide for Retinoblastoma - nutlin-3 For more information visit http://www.researchandmarkets.com/research/r5...noblastoma
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders
Marketwired - Fri Oct 31, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antibiotic applications, is pleased to provide a strategic and operations update to shareholders from the Company's newly appointed Chief Operating Officer, Dr. James Alexander. Cellceutix disclosed in an 8-K filing with the U.S. Securities and Exchange Commission (SEC) on October 24, 2014 that the Board of Directors approved the appointment of Dr. Alexander as COO, effective October 27, 2014.
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
Marketwired - Thu Oct 23, 10:52AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results for its Phase 2b randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The trial, which began in February, enrolled 215 subjects, with approximately 25% in each treatment arm. The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of ABSSSI lesion, relative to baseline, when observed 48-72 hours after the first dose of study drug, and no rescue antibiotics administered. This is consistent with the 2013 Food and Drug Administration (FDA) guidance for ABSSSI studies and is the same endpoint used in recent approvals for ABSSSI drugs.
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis
Marketwired - Mon Oct 13, 8:02AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce that its IND has become effective and that the University of Texas MD Anderson Cancer Center has been selected as a clinical site for Cellceutix's Phase 2 trial of Brilacidin-OM as a novel treatment for oral mucositis. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for treating the approximately 500,000 people each year who have oral mucositis from head and neck cancers, a common and often debilitating condition affecting the mouth and pharynx as a side effect of certain cancer treatments, including chemotherapy and radiation therapy given.
Cellceutix Provides Update to Shareholders
Marketwire - Wed Sep 24, 11:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications today has provided an update to its shareholders.
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health
Marketwire - Fri Sep 19, 6:15AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration's measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
Marketwired - Mon Dec 22, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide additional information from the Company's recently completed Phase 2b clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), as well as information on other pipeline developments. Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.13 (+0.05), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), BCLI: 3.85 (+0.22), OMER: 22.09 (+0.48), NVS: 93.91 (+0.66)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.03), PFNX: 7.33 (-0.05), INO: 9.11 (-0.09), CMRX: 36.80 (+0.70), RPTP: 9.34 (+0.56), IBIO: 0.68 (-0.04), ANAC: 30.58 (+0.16), PFE: 31.42 (-0.03), GNCA: 7.42 (-0.11), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)
Otitis Media - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/2cm2ck/otitis_media) has announced the addition of the "Otitis Media - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Otitis Media - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alcon, Inc. - GlaxoSmithKline plc - Yuhan Corporation - Arbor Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Otonomy, Inc. - Cellceutix Corporation - Serum Institute of India Limited - BCO Pharma Ltd For more information visit http://www.researchandmarkets.com/research/2c...itis_media
GSK: 42.85 (+0.11), OTIC: 32.26 (+0.65)
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin
Marketwired - Wed Dec 10, 6:40AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis. Cellceutix conducted a Phase 1 study which demonstrated that the bioavailability of the active component of Prurisol (abacavir) was the same or lower than that of the marketed drug Ziagen(R) (abacavir sulfate). FDA noted at the end-of-Phase 1 meeting on December 8, 2014 that, pending the full review of the Phase 1 data, long-term safety data for Prurisol in the treatment of psoriasis would not be required. Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 57.46 (+0.25), PBS.VN: 0.015 (unch), NVS: 93.91 (+0.66)
Cellceutix jumps on QIDP tag
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 12:23PM CST
CBST: 100.29 (-0.09)
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
Marketwired - Mon Dec 08, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix's planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company's lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin. Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.38 (unch)
Super Stock Profits OTC Daily Trading News: Cellceutix Corp, Virtus Oil and Gas Corp, Solar 3D, Inc. Alkame Holdings, Inc.
PR Newswire Europe - Wed Nov 26, 7:39AM CST
LONDON, September 30, 2014 /PRNewswire/ --
Cellceutix: December to Be Momentous Month in Company's History
Marketwired - Mon Nov 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the completion of the ninth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The safety committee overseeing the clinical trial will be meeting in the first week of December to review safety data and discuss a possible dose escalation for the tenth cohort. These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
ACCESSWIRE - Wed Nov 12, 8:53AM CST
CORAL GABLES, FL / ACCESSWIRE / November 12, 2014 / The midterm elections are still fresh in our minds and as several sectors have suffered due to the Republican party taking control, others have prospered. Moreover medical stocks have benefited greatly from this recent turn-over of power on Capitol Hill as certain changes are being made to the Affordable Care Act. Over the last week, companies involved in the healthcare and biotech sectors have enjoyed more of a marketwide revival in stock price appreciation.
Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014
Marketwired - Tue Nov 11, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antibiotic applications, is pleased to report that enrollment of the first patient in the Company's Phase 2 clinical trial of Brilacidin-OM for oral mucositis, an often debilitating effect of certain cancer therapies, is targeted for December 2014. Procedural work is being conducted at University of Texas MD Anderson Cancer Center as well as other clinical sites participating in the study. Cellceutix will soon be updating www.clinicaltrials.gov to reflect the start of the trial. Retinoblastoma Therapeutics Pipeline Review, H2 2014 - 6 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5rnnw/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Neotropix, Inc. - Cellceutix Corporation - Recombio S.L - Icon Bioscience, Inc. - RXi Pharmaceuticals Corporation Drug Profiles - NTX-010 - racotumomab - Kevetrin - BL-8040 - melphalan - RNAi Oligonucleotide for Retinoblastoma - nutlin-3 For more information visit http://www.researchandmarkets.com/research/r5...noblastoma
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders
Marketwired - Fri Oct 31, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antibiotic applications, is pleased to provide a strategic and operations update to shareholders from the Company's newly appointed Chief Operating Officer, Dr. James Alexander. Cellceutix disclosed in an 8-K filing with the U.S. Securities and Exchange Commission (SEC) on October 24, 2014 that the Board of Directors approved the appointment of Dr. Alexander as COO, effective October 27, 2014. Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
Marketwired - Thu Oct 23, 10:52AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results for its Phase 2b randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The trial, which began in February, enrolled 215 subjects, with approximately 25% in each treatment arm. The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of ABSSSI lesion, relative to baseline, when observed 48-72 hours after the first dose of study drug, and no rescue antibiotics administered. This is consistent with the 2013 Food and Drug Administration (FDA) guidance for ABSSSI studies and is the same endpoint used in recent approvals for ABSSSI drugs. Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis
Marketwired - Mon Oct 13, 8:02AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce that its IND has become effective and that the University of Texas MD Anderson Cancer Center has been selected as a clinical site for Cellceutix's Phase 2 trial of Brilacidin-OM as a novel treatment for oral mucositis. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for treating the approximately 500,000 people each year who have oral mucositis from head and neck cancers, a common and often debilitating condition affecting the mouth and pharynx as a side effect of certain cancer treatments, including chemotherapy and radiation therapy given. Cellceutix Provides Update to Shareholders
Marketwire - Wed Sep 24, 11:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications today has provided an update to its shareholders. Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health
Marketwire - Fri Sep 19, 6:15AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration's measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs. 
